Vaxcyte, Inc.
- Jurisdiction
United States - LEI
254900M7NMHTGASX8D95 - ISIN
US92243G1085 (PCVX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Read full profile
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€604.83M - EBIT margin
0.0% - Net income
-€466.99M - Net margin
0.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | May 6, 2025 | $1.00K–$15.00K |
| Jefferson Shreve | April 11, 2025 | $15.00K–$50.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: February 28, 2024 (Q4 2023)